Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment

• Status: Completed
• Trial end date: 2017-08-31
• Target enrollment: 0
• Participant gender: All

Summary

Polypoidal choroidal vasculopathy (PCV) is a disease of the choroidal vasculature, that is often regarded as a sub-type of age-related macular degeneration (AMD). However, PCV response to anti-vascular agents differs from the response of typical AMD.

This study aims at describing the evolution of the best corrected visual acuity (BCVA) in PCV patients, 28 weeks after they receive one injection of intravitreal aflibercept (2mg).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Active polypoidal choroidal vasculopathy,

• Visual acuity superior to 1/10 (20/200) and inferior to 6,25/10 (20/32)

• Age above 45

• No prior intravitreal treatment, or no response to prior treatment by 3 injections of ranibizumab, or disease recurrence after more than 3 months of stability

• Intravitreal injection of aflibercept is indicated by current clinical recommendations

Exclusion Criteria:

• Simultaneous treatment with another anti-VEGM agent

• Diabetic retinopathy

• Personal history of vitrectomy or uveitis

• Personal history laser photocoagulation and/or verteporphin phototherapy

• Tear in the pigmentary epithelium

• Chorioretinitis scar

• Macular atrophy in the pigmentary epithelium

• Treatment with corticosteroids

• Eye surgery less than 3 months before inclusion